Abstracts tagged "Biomarkers"

Abstract Number: 1309 • ACR Convergence 2025
Transcriptomic biomarkers of progression from undifferentiated arthritis to rheumatoid arthritis
Christina Printzis¹, Keerthana Nagesh Prabhu², Regina Sakalyte³, Sigita Stropuviene³ and Damini Jawaheer¹, ¹Northwestern University, Chicago, IL, ²Washington University in St. Louis, St Louis, MO, ³Vilnius University, Faculty of Medicine, Institute of Clinical Medicine, Clinic of Rheumatology, Orthopedics Traumatology and Reconstructive Surgery, Vilnius, Lithuania
Background/Purpose: A broad range (6-55%) of patients classified as having undifferentiated arthritis (UA) tend to progress to rheumatoid arthritis (RA), suggesting that UA in these…
Abstract Number: 0939 • ACR Convergence 2025
Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus
Chengfeng Xue¹, Jingjing Wang¹, Mengwen Huang¹, Ting Liu¹, Panpan Wang¹, Donghai Chen², Xue Wang¹, Yawei Xu¹, Yajun Gong¹, Jun Yang¹, Xiaoshan Yu¹, Ke Wang¹, Yuqing Zhu¹, Kaixuan Zhu¹, Tianqi Tang¹, Wantong Qi¹, Yaqiong Pei¹, Qiyao Zhang¹, Fugang Li², Qingyang Gu¹ and Xiangnan Qiang¹, ¹WuXi AppTec, Shanghai, China (People's Republic), ²WuXi ApptTec, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse clinical and immunological manifestations. Bruton’s tyrosine kinase (BTK) is a crucial intracellular kinase in…
Abstract Number: 0558 • ACR Convergence 2025
Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Julianty Angsana¹, Marta Polak¹, Sharan Nischal¹, Elizabeth Chen¹, Deepika Balakrishna², Ching-Heng Chou¹, Christopher Sisk³, Lynn Tomsho¹, Arun Kannan¹, Cynthia DeKlotz¹, Megan Miller⁴, Joseph Cafone³, Paul Newbold¹, Ya-Wen Yang¹, Monica Leung¹, Dawn Waterworth¹, Nina Sabins¹, Anna Perillo⁵, Andreas Pinter⁶ and Robert Bissonnette⁷, ¹Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ²Johnson & Johnson, San Diego, CA, USA, San Diego, USA, ³Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ⁴Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ⁵The Rockefeller University, New York, NY, USA, New York, NY, ⁶Goethe University Frankfurt, Frankfurt, Germany, Frankfurt, Germany, ⁷Innovaderm Research, Montreal, QC, Canada, Montreal, QC
Background/Purpose: Icotrokinra (ICO), a first-in-class targeted oral peptide that blocks the interleukin (IL)-23R and inhibits IL-23 pathway signaling, is being evaluated in the phase 3…
Abstract Number: 0778 • ACR Convergence 2025
Clinical significance of non-infectious increased procalcitonin in Still’s disease: A predictor of macrophage activation syndrome
Erdem Bektas¹, Burcu Ceren Uludogan², Büşra Fırlatan Yazgan³, Ozgur Can Kilinc⁴, Beste Acar⁴, Oguzhan Omer Kizilkaya⁴, Aysenur Yilmaz⁵, Busra Yuce⁶, serdal Ugurlu⁷, Umut Kalyoncu³, Timucin Kasifoglu² and Cemal Bes⁸, ¹Istanbul University, Institute of Graduate Studies in Health Sciences, Immunology, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁴Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Department of Rheumatology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey, ⁶Department of Internal Medicine, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey, ⁷Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey
Background/Purpose: Still's disease (SD) is a autoinflammatory disease (AID) characterized by a wide range of clinical manifestations and can exhibit life-threatening macrophage activation syndrome (MAS).…
Abstract Number: 0419 • ACR Convergence 2025
Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
Patricia Vega-Fernandez¹, Kelly Rogers², Megan Quinlan-Waters³, Sheila Angeles-Han², Alexei Grom¹, Daniel Lovell¹, Jennifer Huggins⁴, Ekemini Ogbu¹, Amy Cassedy⁵, Sara Szabo¹, Tracy Ting¹, Grant Schulert¹, McKenzie Vater⁶, Hermine Brunner¹, Jackeline Rodriguez-Smith¹ and Katelyn Banschbach⁷, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, CCHMC, ⁴Cincinnati Children's Medical Center, Cincinnati, OH, ⁵Cincinnati Children's hospital medical center, cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Fort Thomas, KY, ⁷cincinnati Children's hospital, Villa Hills, KY
Background/Purpose: Ultrasound-guided synovial biopsy (USGSB) has been recently implemented for clinical and research purposes in adults with inflammatory arthritis. The current use of USGSB in…
Abstract Number: 0119 • ACR Convergence 2025
Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
Elizabeth Sloan¹, Blake Baay², Lynnette Walters², Paola Sparagana², Kristina Ciaglia¹, Simrat Morris¹, Julie Fuller¹, Lorien Nassi¹, Tracey Wright¹ and Ayesha Zia³, ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²Scottish Rite for Children, Dallas, TX, ³UT Southwestern and Children's Medical Center, Dallas, TX
Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…
Abstract Number: 2599 • ACR Convergence 2025
Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites
Beatriz Vellón-García¹, Sagrario Corrales-Díaz-Flores², MARIA ANGELES AGUIRRE ZAMORANO³, Ismael Sanchez-Pareja³, Laura muñoz-Barrera³, Tomás Cerdó³, Pedro Seguí-Azpilcueta⁴, Christian Merlo², Maria del carmen abalos-aguilera², Nuria Barbarroja⁵, Rafaela Ortega-Castro⁶, José-Antonio Gonzalez-Reyes⁷, Alejandro Escudero-contreras², Chary López pedrera⁸, Jose manuel Villalba⁹ and Carlos Pérez Sánchez¹⁰, ¹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ²Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁴Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷Department of Cell Biology, Immunology and Physiology, University of Cordoba (UCO), Agrifood Campus of International Excellence, (ceiA³)., Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁹Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to:1- Characterize the circulating metabolomic signature in APS patients; 2- Investigate the role of hepatic involvement in the pathophysiology of APS;…
Abstract Number: 2381 • ACR Convergence 2025
Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Angela Lu¹, Daming Shao², Ying Jin¹, Luis Chiriboga³, Ming Wu⁴, James Pullman⁵, Anna Broder⁶ and Shudan Wang⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Chicago, Chicago, IL, ³NYU Langone Medical Center, New York City, ⁴Northwell Health, New Hyde Park, ⁵Montefiore Medical Center, Bronx, NY, ⁶Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: The complement system is known to play a central role in the pathogenesis of lupus nephritis (LN), one of the most severe manifestations of…
Abstract Number: 2092 • ACR Convergence 2025
Associations Among Biomarkers, Cytokines, and Ultrasound Features of Knee Osteoarthritis: A Cross-Sectional Analysis in the Johnston County Health Study
Jasmine Kimber¹, Carolina Alvarez², Virginia Kraus³, Janet Huebner³, Liubov Arbeeva⁴, Todd Schwartz⁵, Yvonne Golightly⁶, Richard Loeser⁷ and Amanda Nelson¹, ¹University of North Carolina at Chapel HIll, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³Duke University, Durham, NC, ⁴University of North Carolina, Chapel Hill, Carrboro, NC, ⁵University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of North Carolina, Chapel Hill, NC
Background/Purpose: Osteoarthritis (OA) is a leading cause of disability worldwide, characterized by progressive joint degeneration, chronic pain and functional impairment (PMID: 24024017). While imaging modalities…
Abstract Number: 1836 • ACR Convergence 2025
Emerging Role of B Cell Subtype-Specific Intracytoplasmic Toll-Like Receptor Expression and Serum Eotaxin as Biomarkers in Lupus Nephritis
Jennifer Tiaré Balderas Miranda¹, Yatzil Reyna Juárez², Beatriz Alcalá-Carmona³, Nancy R Mejía Domínguez⁴, María José Ostos Prado³, José Luis Maravillas-Montero⁵, Fabiola Cassiano-Quezada⁶, Guillermo Juárez Vega⁴, karina santana⁷, Jiram Torres Ruiz⁸ and Diana Gómez-Martín⁹, ¹Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ²Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, ³Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ⁴Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Tlalpan, Distrito Federal, Mexico, ⁶Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁷INCMNSZ, Ciudad de México, Federal District, Mexico, ⁸INCMNSZ, Mexico, Federal District, Mexico, ⁹INCMNSZ, Mexico city, Federal District, Mexico
Background/Purpose: B cells play an essential role in lupus nephritis (LN) pathogenesis. However, abnormalities in specific subtypes like age-associated B cells (ABCs) and double negative…
Abstract Number: 1733 • ACR Convergence 2025
Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
Adela Francis-Malave¹, Terri Laufer², Joshua Baker³, Kyra Sacksith⁴, Melissa Batson⁴ and Sokratis Apostolidis³, ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Bala Cynwyd, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: While immune-related adverse events (irAEs) are a commonly reported complication of immune checkpoint inhibitor (ICI) therapy, factors associated with their development remain poorly defined.…
Abstract Number: 1500 • ACR Convergence 2025
Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
Milad Heydari-Kamjani¹, Amir Daneshvar², Dana Nachawati², Elleson Harper², Keri Ann Pfeil², Meghan Gump², Lindsay Frumker³ and Omer Pamuk¹, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ³University hospitals Cleveland medical center, Highland Heights, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with heterogeneous hematologic manifestations. Thrombocytopenia (TP) in SLE may be associated with major organ involvement…
Abstract Number: 1285 • ACR Convergence 2025
Investigating the Relationship Between Brain Injury Markers and Brain Volume in Children with Systemic Lupus Erythematosus and Healthy Controls
Ganesh Ramanathan¹, Diana Valdes Cabrera², Oscar Mwizerwa³, Justine Ledochowski², Tala El Tal⁴, Sarah Mossad⁵, Ibrahim Mohamed¹, Joanna Law⁶, Lawrence Ng⁷, Paris Moaf², Asha Jeyanathan⁶, Adrienne Davis⁶, Ann Yeh⁶, Linda Hiraki², Deborah Levy², Zahi Touma⁸, Joan Wither⁹, Busisiwe Zapparoli¹⁰, Ashley Danguecan⁵ and Andrea Knight⁵, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁵Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰The Hospital for Sick Children, Etobicoke, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at high risk for neuropsychiatric involvement as disease onset typically occurs during the critical period of…
Abstract Number: 0901 • ACR Convergence 2025
Data-Driven Metabolomics Identifies Diagnostic Signatures and Patient Subgroups in Systemic Autoimmune Disorders
Chary López pedrera¹, Antonio Perez-Campoamor², Gema Dolores García-Delgado³, Beatriz Vellón-García⁴, Adrián Llamas Urbano⁵, Laura Romero Zurita⁶, Pedro Ortiz Buitrago⁷, Christian Merlo⁸, Maria del carmen abalos-aguilera⁸, Nuria Barbarroja⁹, Verónica Bolón-Canedo¹⁰, MARIA ANGELES AGUIRRE ZAMORANO¹¹, Rafaela Ortega-Castro¹², Jerusalén Calvo¹³, Lourdes Ladehesa¹⁴, Marta Alarcon-Riquelme¹⁵, Alejandro Escudero-contreras⁸ and Carlos Pérez Sánchez¹⁶, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ²STARTQUAKE S.L., Gijón, Spain/Research Center on Information and Communication Technologies (CITIC), University of A Coruña, A Coruña, Spain, Gijón, Spain, ³Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain., Cordoba, Spain, ⁴Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain/Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain, Cordoba, Spain, ⁵Cobiomic Bioscience SL. EBT University of Cordoba/IMIBIC, Cordoba, Spain., Cordoba, Spain, ⁶Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Córdoba, Spain, ⁷Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁸Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁰Research Center on Information and Communication Technologies (CITIC), University of A Coruña, A Coruña, Spain, A coruña, Spain, ¹¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ¹³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ¹⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ¹⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain
Background/Purpose: This study aims to characterize the metabolomic fingerprint of several systemic autoimmune diseases (SADs) and apply machine learning (ML) techniques to identify disease-specific biomarkers…
Abstract Number: 0883 • ACR Convergence 2025
Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort
Ali Ayla¹, Chenyue Huang², Claudia Pedroza³, Meng Zhang⁴, John VanBuren⁵, Flavia Castelino⁶, Lorinda Chung⁷, Luke Evnin⁸, Tracy Frech⁹, Jessica Gordon¹⁰, Faye Hant¹¹, Laura Hummers¹², Dinesh Khanna¹³, Kimberly Lakin¹⁰, Dorota Lebiedz-Odrobina⁵, Yiming Luo¹⁴, Ashima Makol¹⁵, Maureen Mayes¹⁶, Zsuzsanna McMahan¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson²⁰, Nora Sandorfi²¹, Ami Shah¹², Ankoor Shah²², Victoria Shanmugam²³, Brian Skaug¹, Virginia Steen²⁴, Elizabeth Volkmann²⁵, Carleigh Zahn¹³, Wenjin J Zheng², Elana Bernstein¹⁴ and Shervin Assassi²⁶, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston, Houston, ³UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ⁴UTHealth Houston Division of Rheumatology, Houston, ⁵University of Utah, Salt Lake City, UT, ⁶Massachusetts General Hospital, Boston, MA, ⁷Stanford University, Stanford, CA, ⁸Scleroderma Research Foundation, Brisbane, CA, ⁹Vanderbilt University Medical Center, Nashville, TN, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Columbia University, New York, NY, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶UT Health Houston Division of Rheumatology, Houston, TX, ¹⁷UT Health Houston, Houston, TX, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern Memorial Hospital, Chicago, IL, ²⁰Northwestern University, Chicago, IL, ²¹University of Pennsylvania, Philadelphia, PA, ²²Duke University, Durham, NC, ²³National Institutes of Health, Great Falls, VA, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²⁶Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: The course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable and difficult to predict using clinical variables alone. Therefore, there…

« Previous Page
1
…
7
8
9
10
11
…
109
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].